Literature DB >> 16818772

Roles of the Ig kappa light chain intronic and 3' enhancers in Igk somatic hypermutation.

Matthew A Inlay1, Heather H Gao, Valerie H Odegard, Tongxiang Lin, David G Schatz, Yang Xu.   

Abstract

Somatic hypermutation (SHM) of the rearranged Ig genes is required for the affinity maturation of Abs. SHM is almost exclusively targeted to the rearranged Ig loci, but the mechanism of this gene-specific targeting remains unclear. The Ig kappa L chain locus contains multiple enhancers, including the MAR/intronic (iE(kappa)) and 3' enhancers (3'E(kappa)). Previous transgenic studies indicate that both kappa enhancers are individually necessary for SHM of Igk. In contrast, later studies of Ag-selected V(kappa) genes in 3'E(kappa)(-/-) mice found no absolute requirement for 3'E(kappa) in kappa SHM. To address the roles of the two kappa enhancers in SHM in a physiological context, we analyzed SHM of the endogenous Igk in mice with a targeted deletion of either iE(kappa) or 3'E(kappa) in Peyer's patch germinal center B cells. Our findings indicate that, although 3'E(kappa) is quantitatively important for SHM of Igk, iE(kappa) is not required for kappa SHM. In addition, a reduction of kappa mRNA levels is also detected in activated 3'E(kappa)(-/-) B cells. These findings suggest that iE(kappa) and 3'E(kappa) play distinct roles in regulating Igk transcription and SHM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818772     DOI: 10.4049/jimmunol.177.2.1146

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Immunoglobulin kappa enhancers are differentially regulated at the level of chromatin structure.

Authors:  Barbara S Nikolajczyk; Sylvia H Sardi; Joseph R Tumang; Lisa M Ganley-Leal
Journal:  Mol Immunol       Date:  2007-03-26       Impact factor: 4.407

2.  JH6 downstream intronic sequence is dispensable for RNA polymerase II accumulation and somatic hypermutation of the variable gene in Ramos cells.

Authors:  Diana P Castiblanco; Darrell D Norton; Robert W Maul; Patricia J Gearhart
Journal:  Mol Immunol       Date:  2018-04-04       Impact factor: 4.407

Review 3.  What Targets Somatic Hypermutation to the Immunoglobulin Loci?

Authors:  Justin M H Heltzel; Patricia J Gearhart
Journal:  Viral Immunol       Date:  2019-11-26       Impact factor: 2.257

4.  A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Ig Sequencing Data.

Authors:  Ang Cui; Roberto Di Niro; Jason A Vander Heiden; Adrian W Briggs; Kris Adams; Tamara Gilbert; Kevin C O'Connor; Francois Vigneault; Mark J Shlomchik; Steven H Kleinstein
Journal:  J Immunol       Date:  2016-10-05       Impact factor: 5.422

Review 5.  Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination.

Authors:  Joyce K Hwang; Frederick W Alt; Leng-Siew Yeap
Journal:  Microbiol Spectr       Date:  2015-02

Review 6.  Targeting of AID-mediated sequence diversification to immunoglobulin genes.

Authors:  Naga Rama Kothapalli; Sebastian D Fugmann
Journal:  Curr Opin Immunol       Date:  2011-02-02       Impact factor: 7.486

7.  The Downstream Transcriptional Enhancer, Ed, positively regulates mouse Ig kappa gene expression and somatic hypermutation.

Authors:  Yougui Xiang; William T Garrard
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 8.  Generation and repair of AID-initiated DNA lesions in B lymphocytes.

Authors:  Zhangguo Chen; Jing H Wang
Journal:  Front Med       Date:  2014-04-21       Impact factor: 4.592

Review 9.  A coming-of-age story: activation-induced cytidine deaminase turns 10.

Authors:  Rebecca K Delker; Sebastian D Fugmann; F Nina Papavasiliou
Journal:  Nat Immunol       Date:  2009-10-20       Impact factor: 25.606

10.  A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation.

Authors:  Artem Blagodatski; Vera Batrak; Sabine Schmidl; Ulrike Schoetz; Randolph B Caldwell; Hiroshi Arakawa; Jean-Marie Buerstedde
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.